These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32779747)

  • 1. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.
    Karnes JH; Rettie AE; Somogyi AA; Huddart R; Fohner AE; Formea CM; Ta Michael Lee M; Llerena A; Whirl-Carrillo M; Klein TE; Phillips EJ; Mintzer S; Gaedigk A; Caudle KE; Callaghan JT
    Clin Pharmacol Ther; 2021 Feb; 109(2):302-309. PubMed ID: 32779747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
    Caudle KE; Rettie AE; Whirl-Carrillo M; Smith LH; Mintzer S; Lee MT; Klein TE; Callaghan JT;
    Clin Pharmacol Ther; 2014 Nov; 96(5):542-8. PubMed ID: 25099164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Chang WC; Hung SI; Carleton BC; Chung WH
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):723-734. PubMed ID: 32510242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population.
    Tassaneeyakul W; Prabmeechai N; Sukasem C; Kongpan T; Konyoung P; Chumworathayi P; Tiamkao S; Khunarkornsiri U; Kulkantrakorn K; Saksit N; Nakkam N; Satapornpong P; Vannaprasaht S; Sangviroon A; Mahasirimongkol S; Wichukchinda N; Rerkpattanapipat T; Tassaneeyakul W
    Pharmacogenet Genomics; 2016 May; 26(5):225-34. PubMed ID: 26928377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.
    Leckband SG; Kelsoe JR; Dunnenberger HM; George AL; Tran E; Berger R; Müller DJ; Whirl-Carrillo M; Caudle KE; Pirmohamed M;
    Clin Pharmacol Ther; 2013 Sep; 94(3):324-8. PubMed ID: 23695185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
    Phillips EJ; Sukasem C; Whirl-Carrillo M; Müller DJ; Dunnenberger HM; Chantratita W; Goldspiel B; Chen YT; Carleton BC; George AL; Mushiroda T; Klein T; Gammal RS; Pirmohamed M
    Clin Pharmacol Ther; 2018 Apr; 103(4):574-581. PubMed ID: 29392710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CYP2C9*3 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis.
    Wu X; Liu W; Zhou W
    J Clin Pharm Ther; 2018 Jun; 43(3):408-413. PubMed ID: 29274302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
    Hershfield MS; Callaghan JT; Tassaneeyakul W; Mushiroda T; Thorn CF; Klein TE; Lee MT
    Clin Pharmacol Ther; 2013 Feb; 93(2):153-8. PubMed ID: 23232549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
    Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
    JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.
    Locharernkul C; Loplumlert J; Limotai C; Korkij W; Desudchit T; Tongkobpetch S; Kangwanshiratada O; Hirankarn N; Suphapeetiporn K; Shotelersuk V
    Epilepsia; 2008 Dec; 49(12):2087-91. PubMed ID: 18637831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children.
    Manuyakorn W; Likkasittipan P; Wattanapokayakit S; Suvichapanich S; Inunchot W; Wichukchinda N; Khongkhatithuml C; Thampratankul L; Kamchaisatian W; Benjaponpitak S; Mahasirimongkol S
    Epilepsy Res; 2020 May; 162():106321. PubMed ID: 32272329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
    Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
    Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.
    Theken KN; Lee CR; Gong L; Caudle KE; Formea CM; Gaedigk A; Klein TE; Agúndez JAG; Grosser T
    Clin Pharmacol Ther; 2020 Aug; 108(2):191-200. PubMed ID: 32189324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.
    Yampayon K; Sukasem C; Limwongse C; Chinvarun Y; Tempark T; Rerkpattanapipat T; Kijsanayotin P
    Eur J Clin Pharmacol; 2017 Jul; 73(7):855-865. PubMed ID: 28391407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V; Perucca E
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1269-79. PubMed ID: 26037375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of association of Stevens-Johnson syndrome/toxic epidermal necrolysis due to aromatic anticonvulsants and HLA-B alleles in South Indian children.
    Srinivas SM; Gowda VK; Gowdra A; Gangasamudra Veerappa B; Kumar P
    Int J Dermatol; 2024 May; 63(5):e97-e99. PubMed ID: 38415927
    [No Abstract]   [Full Text] [Related]  

  • 18. Coupling Genotyping and Computational Modeling in Prediction of Anti-epileptic Drugs that cause Stevens Johnson Syndrome and Toxic Epidermal Necrolysis for Carrier of HLA-B*15:02.
    Teh LK; Selvaraj M; Bannur Z; Ismail MI; Rafia H; Law WC; Sapuan S; Puvanarajah S; Ali PS; Salleh MZ
    J Pharm Pharm Sci; 2016; 19(1):147-60. PubMed ID: 27096699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project.
    Hikino K; Ozeki T; Koido M; Terao C; Kamatani Y; Mizukawa Y; Shiohara T; Tohyama M; Azukizawa H; Aihara M; Nihara H; Morita E; Murakami Y; Kubo M; Mushiroda T
    Clin Pharmacol Ther; 2020 May; 107(5):1170-1178. PubMed ID: 31646624
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.